AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT02636283
Drug: Placebo group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo pills
Trial: NCT03418675
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pill that contains no medicine
Trial: NCT02590510
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The quantity of methotrexate is different in the two groups.
Trial: NCT00145327
Drug: Zoledronic Acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Zoledronic Acid 5 mg in 100 mL physiologic 0.9% normal saline for intravenous infusion.
Trial: NCT00145327
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mL physiologic 0.9% normal saline for intravenous infusion.
Trial: NCT03532490
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The first two weeks the participant will take one tablet every other day. If well tolerated, participant will take one tablet every day.
Trial: NCT01795937
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: single dose
Trial: NCT01037465
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT04097912
Drug: Acetylsalicylic Acid (Aspirin, BAYE4465)
RxNorm normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 75-100mg
Trial: NCT03315689
Drug: Vehicle
RxNorm normalized name: Drug vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle Topical Solution
Trial: NCT01507727
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo plus conventional therapy according to each patient's underlying disease, such as CHF, hepatic cirrhosis and SIADH or others.
Trial: NCT03715166
Drug: Bumetanide Oral Solution
RxNorm normalized name: bumetanide Oral Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Solution dosed at 0.5mg/mL Taken twice daily
Trial: NCT03715166
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Solution Taken twice daily
Trial: NCT03663725
Drug: Intensified protocol
RxNorm normalized name: Olay Professional Acne Protocol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early Temozolomide (TMZ) 1 cycle (150 mg/m²/ day X 5 days, per os) Started between day 2 and 15 after surgery/ biopsy RT (60 Gy, 2 Gy/fraction) + concomitant TMZ (75 mg/m2/day X 42 days, per os) Started between W4 and W6 after surgery/ biopsy Adjuvant TMZ 6 cycles (150-200 mg/m2 X 5 days /month, per os) Started 1 month after the end of the concomitant TMZ Prolonged TMZ Until progression, intolerance, patient's or physician's decision (150-200 mg/m2 every 4 weeks, per os)
Trial: NCT03663725
Drug: Stupp protocol
RxNorm normalized name: Olay Professional Acne Protocol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RT (60 Gy, 2 Gy/fraction) + concomitant Temozolomide (75 mg/m2/day X 42 days, per os) Started between W4 and W6 after surgery/ biopsy Adjuvant TMZ 6 cycles (150-200 mg/m2 X 5 days /month, per os) Started 1 month after the end of the concomitant TMZ
Trial: NCT03447756
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo to match
Trial: NCT05951842
Drug: anesthetic method
RxNorm normalized name: Gelato Anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be assigned to one of the groups, TIVA group or Balanced anesthesia group. In TIVA group, anesthesia will be maintained by propofol and remifentanil infusion under target controlled infusion. In contrast, anesthesia will be maintained by sevoflurane and remifentanil infusion in the balanced anesthesia group.
Trial: NCT03943992
Drug: YYD601 40mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients should take druges 30 minutes before breakfast.
Trial: NCT03943992
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo YYD601 is made from microcrystalline cellulose covered with hard shell. The placebo Nexium is made from microcrystalline cellulose, Crospovidone, Magnesiumstearat and other ingredients.
Trial: NCT00669331
Drug: Matched control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50mg dose of Mannitol BD (twice a day) for 52 weeks
Trial: NCT04124510
Drug: Brand Name: Flutiform K-haler
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brand Name: Flutiform K-haler Generic name: Fluticasone/formoterol dosage form: oral inhalation
Trial: NCT01769118
Drug: Caffeine
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Caffeine will be given according to departmental protocol
Trial: NCT03564145
Drug: S5G4T-1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once a day topical cream
Trial: NCT01590966
Drug: administration of Cimzia®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be treated with prefilled syringes containing each 200 mg/ml Cimzia® every 2 weeks which will be administered subcutaneously (The first 3 injections, a dosage of 400mg Cimzia® subcutaneously will be administered).
Trial: NCT01590966
Drug: Immunoscintigraphy with radiolabeled Cimzia®.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All 20 patients will undergo an immunoscintigraphy with radiolabeled Cimzia®. Certolizumab pegol (Cimzia®) is an engineered humanized monoclonal antibody Fab' fragment with specificity for human TNF-α, manufactured in E. coli. The antibody fragment is subsequently purified and conjugated with high molecular weight polyethylene glycol (PEG) (40kDa). Lyophilized Cimzia® will be conjugated with S-HYNIC (a bifunctional chelator). The conjugate will be radiolabeled with Tc-99m by adding 0.1 mg Tricine, 0.01 mg SnSO4 and 750 MBq Tc-99m pertechnetate. A dose of 750 MBq Tc-99m Cimzia® will be injected intravenously.
Trial: NCT00249041
Drug: Enbrel liquid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg Etanercept liquid injected SC once weekly using prefilled syringes
Trial: NCT00211939
Drug: calcium acetate
RxNorm normalized name: Calcium Acetate
DrugBank: Calcium sulfate (DB15533)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 667 mg gelcap, 2-4 t.i.d titrated to serum phosphorus level
Trial: NCT03561740
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: additional metronomic chemotherapy of capecitabine
Trial: NCT01058824
Drug: Lincomycin
RxNorm normalized name: Lincomycin
DrugBank: Lincomycin (DB01627)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single Dose Hard Gelatin Capsule - oral - 500 mg
Trial: NCT00421733
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group 1 - Placebo once daily (two placebo capsules once daily)
Trial: NCT00712049
Drug: simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: simvastatin 40 mg
Trial: NCT00676052
Drug: GSK233705 12.5mcg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily via dry powder inhaler
Trial: NCT00676052
Drug: GSK233705 25mcg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: once daily via dry powder inhaler
Trial: NCT00676052
Drug: GSK233705 50mcg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily via dry powder inhaler
Trial: NCT00676052
Drug: GSK233705 100mcg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily via dry powder inhaler
Trial: NCT00676052
Drug: GSK233705 200mcg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily via dry powder inhaler
Trial: NCT00676052
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily via dry powder imhaler
Trial: NCT02587364
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo once daily (QD)
Trial: NCT00407030
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT04243837
Drug: Placebo BCRL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BCRL patients will receive Placebo BID for 6 months
Trial: NCT02200445
Drug: Interleukin-2 (aldesleukin).
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Description of intervention is covered in Arm, above.
Trial: NCT00066170
Drug: Xyrem Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xyrem Placebo oral solution 12 ml per day for 4 weeks and 18 ml per day for another 4 weeks.
Trial: NCT01049672
Drug: Diamorphine
RxNorm normalized name: Diamorphine
DrugBank: Diamorphine (DB01452)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Titrated to a maximum dose of 500mg in 24 hours given subcutaneously
Trial: NCT00769405
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00769405
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT02524678
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02524678
Drug: URC102
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00430859
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline over a period of 24h
Trial: NCT00106535
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV/month
Trial: NCT00106535
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 10-25 mg/week
Trial: NCT02072993
Drug: AZD1979
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose, oral solution administration
Trial: NCT02072993
Drug: Placebo to match
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose, oral solution administration
Trial: NCT02945046
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matching to fremanezumab will be administered per schedule specified in the arm.
Trial: NCT01194700
Drug: Seretide 250 (8 puffs)/placebo via Volumatic spacer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 puffs of Seretide 250/placebo via volumatic spacer
Trial: NCT01194700
Drug: Seretide 250/placebo via Synchro-Breathe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Seretide 250/placebo 8puffs via breath actuated Synchro-Breathe device
Trial: NCT01738178
Drug: Caffeine
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01738178
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02838238
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02838238
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03985995
Drug: CBD 800 mg p.o
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cannabidiol solution 100 mg/ml 8 ml in single-dose containers for per os administration. After a washout period of at least two weeks, the treatment group will be receiving a single-dose of the placebo solution 8 ml as a second intervention.
Trial: NCT03985995
Drug: Placebo p.o
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single dose of oral placebo solution 8 ml matched to the IMP. After a washout period of at least two weeks, the control intervention group will be receiving the cannabidiol solution 100 mg/ml 8 ml as a second intervention.
Trial: NCT01252940
Drug: FTC/RPV/TDF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Emtricitabine (FTC) 200 mg/rilpivirine (RPV) 25 mg/tenofovir disoproxil fumarate (tenofovir DF; TDF) 300 mg single-tablet regimen (STR) administered orally with a meal once daily (QD)
Trial: NCT01252940
Drug: RTV
RxNorm normalized name: Accu-Chek SmartView Test Strips
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ritonavir (RTV) was administered according to prescribing information.
Trial: NCT01252940
Drug: NRTIs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NRTIs included abacavir, emtricitabine, Combivir (lamivudine/zidovudine, coformulated), Epzicom (abacavir/lamivudine, coformulated), lamivudine, stavudine, tenofovir DF, Truvada® (emtricitabine/tenofovir DF, coformulated), and zidovudine. NRTIs were administered according to prescribing information.
Trial: NCT00001339
Drug: doxorubicin, vincristine, and etoposide with mitotane
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00001596
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (3 pills), three times daily.
Trial: NCT00593255
Drug: soluble human insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00593255
Drug: insulin NPH
RxNorm normalized name: insulin NPH human isophane
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01113957
Drug: pegylated liposomal doxorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arm B subjects randomized to pegylated liposomal doxorubicin on Day 1, every 28 days intravenously.
Trial: NCT03432689
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsule matched to cycloserine capsule
Trial: NCT04774874
Drug: Topical formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical administration on the scalp once daily for 16 weeks
Trial: NCT00074087
Drug: pegylated liposomal doxorubicin hydrochloride
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00463346
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT01572909
Drug: Bendavia (MTP-131)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.05 mg/kg/hr
Trial: NCT01572909
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Identically appearing placebo
Trial: NCT03259308
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive 1 mL of sterile aqueous buffered solution.
Trial: NCT00996177
Drug: IONSYS (fentanyl HCl) Iontophoretic TransdermalSystem
RxNorm normalized name: fentanyl Transdermal System [Ionsys]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 µg fentanyl on-demand (240µg/hr) or a maximum of 80 doses (3.2 mg) per day
Trial: NCT02455180
Drug: Ascorbic Acid
RxNorm normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients receive vitamin C 4 times in either high (5g) or moderate (1g) dose. Vitamin C will be administered intravenously (ascorbinezuur CF 100 mg/ml, Centrafarm BV, Etten Leur, Netherlands) in 50ml of NaCl 0.9%, infused over 30 minutes.
Trial: NCT04324489
Drug: DAS181
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient receives nebulized DAS181 (4.5 mg BID/day, a total 9 mg/day) for 10 days.
Trial: NCT04701320
Drug: Conventional glass ionomer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional glass ionomer with enhanced mechanical and esthetic proberties
Trial: NCT04701320
Drug: Nano hydroxyapatite reinforced glass ionomer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nanohydroxyapatite reinforced glass ionomer restorative material with enhanced mechanical proberties and chemical adhesion to tooth structure
Trial: NCT00105508
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive placebo matched to sarizotan orally twice daily for 24 weeks.
Trial: NCT04607382
Drug: NSAIDs and/or Chinese medicine (CM)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Chinese medicine (CM) dosage up to the discretion of the treating gynecologists.
Trial: NCT00922389
Drug: Standard Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Any thing directed to improve blood perfusion in the limb example.Heparin,Antiplatelet agents etc
Trial: NCT00003474
Drug: Antineoplaston therapy (Atengenal + Astugenal)
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adults with a residual/recurrent/progressive Glioblastoma Multiforme will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1.
Trial: NCT03123107
Drug: Ascorbic Acid
RxNorm normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ascorbic acid doses will be mixed in 100 mL normal saline and infused over 60 minutes. The postoperative dose will be given on postoperative day #1.
Trial: NCT03158311
Drug: QVM149
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indacaterol acetate / glycopyrronium bromide / mometasone furoate
Trial: NCT01018953
Drug: BIM 23A760
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BIM 23A760 is a solution at a concentration of 5 mg/mL ready for subcutaneous injection. BIM 23A760 dose of 1, 2, 4, 6 and 8 mg can be given to the patient according to a dose escalation and titration process. Patients will receive 24 weekly injections of BIM 23A760 during the treatment period. Patients eligible to continue the extension phase will be administered BIM 23A760 for further 52 weekly injections.
Trial: NCT03927716
Drug: SB206 12%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topically once daily
Trial: NCT03927716
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topically once daily
Trial: NCT03853200
Drug: QMix Root Canal Irrigant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endodontic irrigant recommended for final irrigation
Trial: NCT04483947
Drug: AZD2693
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous administration of AZD2693 multiple ascending doses in participants with NASH and who are carriers of the PNPLA3 148M risk allele(s).
Trial: NCT02416271
Drug: Placebo-Oral
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT02416271
Drug: Placebo-SC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC
Trial: NCT02857959
Drug: Benzathine Penicillin G
RxNorm normalized name: Benzathine penicillin G
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01075204
Drug: clarithromycin modified release 500 mg
RxNorm normalized name: clarithromycin Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: clarithromycin modified release 500 mg for 7 days
Trial: NCT00651807
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Every day one tablet up to 8 weeks
Trial: NCT04028960
Drug: Regular insulin (Humulin-R), intranasal route
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Humulin-R insulin is approved by the U.S. Food and Drug Administration (FDA) for the treatment of diabetes.
Trial: NCT00954538
Drug: [18F]MK-3328
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV dose of \~150 megabecquerel (MBq) \[18F\]MK-3328
Trial: NCT00853047
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo-matching telotristat etiprate capsules; orally 3 times daily.
Trial: NCT01164969
Drug: Antibiotics to which H. pylori can not develope resistance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin, metronidazole and tetracyclin as primary drugs to treat H. pylori infection in duration of 10 days.
Trial: NCT02740582
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02149160
Drug: FRM-0334
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02149160
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02113566
Drug: Acetaminophen 1000mg
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects who require rescue medication between hours 4 and 6 will be allowed to take Dose 2 of the study medication. If the subject chooses to take a rescue analgesic (acetaminophen 1000mg), they will be considered a treatment failure. This intervention will be use for the placebo and Ibuprofen arm.
Trial: NCT01797185
Drug: SPARC1104 modified dose regimen I
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects who exited study CLR_09_21
Trial: NCT01797185
Drug: SPARC1104 modified dose regimen II
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects who received prior treatment regimen I
Trial: NCT01797185
Drug: SPARC1104 modified dose regimen III
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects who received no prior treatment regimen
Trial: NCT02204462
Drug: FBnTP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A PET imaging radiotracer
Trial: NCT02015715
Drug: RO6864018
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single oral ascending dose of RO6864018 capsules on Day 1.
Trial: NCT02015715
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single oral dose of placebo matching RO6864018 capsules on Day 1.
Trial: NCT01882621
Drug: Monosialoganglioside(GM1)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80mg,ivdrip (in the vein) on day 0 - day 3 of each 21 day cycle. Number of Cycles: 4-6 cycles.
Trial: NCT01882621
Drug: normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80mg,ivdrip(in the vein) on day 0-3 of each 21 day cycle. Number of Cycles: 4-6 cycles.
Trial: NCT03407378
Drug: IPT803
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of IPT803 three times a day for 12 weeks as add-on therapy to patient regular PD medication(s) or as a new therapy for drug naïve patients.
Trial: NCT02753101
Drug: [18F]-FTC-146
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mCi± 1 mCi of \[18F\]FTC-146 intravenously
Trial: NCT01199523
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral